02:59:53 EDT Sun 16 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Z:MRK - MERCK & CO INC - http://www.merck.com02:59:53 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRK - Z0.178.28·78.520.178.29-0.40-0.57,894.2620,68862,92279.06  79.15  78.2287.80  71.71519:59:26May 1315 min RT 2¢

Recent Trades - Last 10 of 62922
Time ETExPriceChangeVolume
19:59:26Z78.28-0.4110
19:35:26Z78.50-0.196
19:28:55Z78.49-0.201
18:58:18Z78.720.0310
18:58:18Z78.750.0690
18:58:18Z78.58-0.111
18:51:41Z78.51-0.18123
18:36:53Z78.51-0.18500
18:36:38Z78.49-0.20376
18:36:38Z78.50-0.191

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-05-13 06:45U:MRKNews ReleaseMerck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2021-05-07 13:01U:MRKNews ReleaseMerck Declares Record Date and Dividend for the Organon & Co. Spinoff
2021-05-06 06:45U:MRKNews ReleaseMerck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
2021-05-06 06:30U:MRKNews ReleaseMerck and Eisai Receive Priority Review From FDA for KEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
2021-05-05 16:05U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2021-05-03 06:45U:MRKNews ReleaseMerck Hosts Organon Investor Day Outlining New Company ’s Vision, Focus and Business Model for Sustained Growth
2021-04-29 06:30U:MRKNews ReleaseMerck Announces First-Quarter 2021 Financial Results
2021-04-27 06:47U:MRKNews ReleaseMerck to Hold Investor Briefing Featuring Organon on May 3
2021-04-27 06:45U:MRKNews ReleaseAmid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
2021-04-26 06:45U:MRKNews ReleaseMerck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025